Skip to Content
Merck

PZ0180

Delavirdine mesylate

≥98% (HPLC)

Synonym(s):

N-[2-[[4-[3-[(1-Methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]methanesulfonamide mesylate, Rescriptor

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H28N6O3S · CH3SO3H
CAS Number:
147221-93-0
Molecular Weight:
552.67
NACRES:
NA.77
PubChem Substance ID:
329823754
UNSPSC Code:
51111800
MDL number:
MFCD00866948
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Delavirdine mesylate, ≥98% (HPLC)

InChI key

MEPNHSOMXMALDZ-UHFFFAOYSA-N

SMILES string

CS(O)(=O)=O.CC(C)Nc1cccnc1N2CCN(CC2)C(=O)c3cc4cc(NS(C)(=O)=O)ccc4[nH]3

InChI

1S/C22H28N6O3S.CH4O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-5(2,3)4/h4-8,13-15,24-26H,9-12H2,1-3H3;1H3,(H,2,3,4)

assay

≥98% (HPLC)

form

powder

color

white to tan

mp

315 °C

solubility

DMSO: >5 mg/mL

storage temp.

room temp

Quality Level

100

Biochem/physiol Actions

Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1.
Non-nucleoside reverse transcriptase inhibitor (NNRTI); Anti-retroviral.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000489044
0000489043
0000489043
0000489044
0000361282

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shauna A Clark et al.
AIDS (London, England), 20(7), 981-984 (2006-04-11)
HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI) improves the response to NNRTI-containing regimens. The genetic basis for NNRTI hypersusceptibility was partly defined in our earlier analyses of a paired genotype-phenotype dataset of viral isolates from treatment-experienced patients, in which
Margaret Reid et al.
Midwifery, 27(1), 30-35 (2010-01-05)
to explore women's experiences of cervical ripening using isosorbide mononitrate (IMN) in the home as part of the main randomised controlled trial. qualitative study with semi-structured interviews carried out at three weeks post partum. Interview transcripts were analysed to identify
Elinore F McCance-Katz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 Suppl 4, S224-S234 (2006-11-17)
This study examined drug interactions between buprenorphine, an opioid partial agonist medication used in the treatment of opioid dependence, and the nonnucleoside reverse-transcriptase inhibitors (NNRTIs) efavirenz (EFV) and delavirdine (DLV). Opioid-dependent, buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers (n=10 per NNRTI)
Zhengqiang Wang et al.
Bioorganic & medicinal chemistry, 16(7), 3587-3595 (2008-03-04)
Cost and toxicity problems associated with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs). Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid
Qing Xia et al.
Protein science : a publication of the Protein Society, 16(8), 1728-1737 (2007-07-28)
Nonnucleoside reverse transcriptase inhibitors (NNRTI) are a group of structurally diverse compounds that bind to a single site in HIV-1 reverse transcriptase (RT), termed the NNRTI-binding pocket (NNRTI-BP). NNRTI binding to RT induces conformational changes in the enzyme that affect
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service